A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.
Peter Meath, who heads the Life Science Group at J.P. Morgan’s Commercial Banking business, offers advice to novice entrepreneurs for turning a company’s novel science into a viable business.
Bridging to commercialization of women’s reproductive health products — starting with a novel contraceptive.
In the December 2017 issue’s article, “The Women of Biopharma — Will They Gain or Lose Ground in 2018?” we summarize the responses of those who chose to contribute as panelists in a “virtual roundtable” discussion. Here, as promised, we are posting their written responses in full.
We hear from 11 women and one man in biopharma. Although we were not aiming for “balance” here — there are plenty of opposing opinions out there already — the sole gender-exception in this group supplies another valuable viewpoint…
With 24 employees, Paris-based Abivax is in Phase 2 clinical development of its lead drug candidate, which is a potential functional cure for HIV infection. It has also recently spawned an early clinical program in inflammatory bowel disease (IBD).
Deborah Dunsire has lived and worked in a world driven by commercial drug development for three decades. She’s worked for Big Pharmas such as Novartis and Sandoz and is now trying her hand at managing a small pharma as president & CEO of XTuit. For sure, she’s been a pioneer — but she’s not done yet.
Madrigal Pharmaceuticals is taking on NASH and other liver diseases by targeting the thyroid hormone beta receptor. The company expects to begin seeing top line Phase 2 trial results in late 2017, with more released in 2018.
Always stick with your original goals, even when you reap another, off-the-scale success. Like many biopharma companies, Prometic invented a novel technology platform, initially to make new medicines available to unserved populations.
Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.
By early 2016, Arena’s board decided to remake the company, beginning with new management and a new strategy. Since then, the company has evolved back to a core drug development platform.
Oncology isn’t the only therapeutic area subject to the hyperbole of hope. It is just the most perfect example of hype, an all-too-common state of mind in the “cancer community.
Cynthia Schwalm, president, North American commercial operations for Ipsen, gives the backstory of what happened when this company decided to change its approach to the U.S. market.
ProMIS Neurosciences believes inaccurate targeting of mAbs is to blame, in fact, for lack of progress against Alzheimer’s disease.